American Cancer Society Journals’ Post

Breakthrough Study Reveals Key Mechanism in Breast Cancer Metastasis Prevention A groundbreaking study published in Cell reveals that lung-resident alveolar macrophages (AMs) suppress the spread of breast cancer by inducing dormancy in disseminated cancer cells, offering new prospects for preventing metastatic breast cancer. Link to the news article: https://lnkd.in/gF3hrSxG #breastcancer #metastasis #cancertherapy #immunotherapy #macrophages Albert Einstein College of Medicine Erica Dalla, Ph.D. Michael Papanicolaou Matthew D. Park, Ph.D. Luis Valencia Salazar MARIA CASANOVA ACEBES David Entenberg Miriam Merad, MD, PhD Julio Aguirre-GhisoMathias Schulz MD, MBA Julie Porter Robin Gingold Adeline Wang Riley Jones, PhD Jennifer Brzezinski Akihiko K. Maria Denslow Earl Albone Arnaud Charil Christine Carruth Laura van 't Veer Dr. Angela Honegger Harjinder Singh, MD, FCCP Natalie Farris Shu-Chih Chen Deborah Knee Detlef Reinhard Schiwek Luis M Blancas-Mejia Kah-Whye Peng Jan Witowski MD PhD Allison Keith Macaulay, MS/PhD Ky McCracken Ross Kopher, MS, PhD Tripti Gaur John (Haiqun) Jia Sung Hugh Choi Cynthia Bamdad Andrew Stewart Dominic Kowalski   ·   

📌Young Breast Cancer Patients: Challenges and the Situation in Egypt At the 17th Breast Gynecological & Immunooncology International Cancer Conference-BGICC, Prof. Hesham ElGhazaly discussed the rising burden of breast cancer among young patients, with a special focus on Egypt. His presentation highlighted key epidemiological trends, unique challenges, and potential solutions for improving outcomes in this vulnerable population. #BreastCancer #BGICC2025 #CancerResearch #Egypt #OncoDaily #Oncology #Cancer #Health #Medicine

I was honored to present our #research at the 2024 San Antonio Breast Cancer Symposium, focusing on the first known cohort of patients with early-stage, high-risk, hormone receptor-positive HER2-negative breast cancer who experienced recurrence while on adjuvant #abemaciclib. Out of 163 patients treated in this setting, 9.2% (n=15) experienced recurrence. Among the 12 patients with hormone receptor status available at recurrence, we observed hormone receptor loss in 50% (6/12). Additionally, next-generation sequencing of recurrence biopsies revealed p53 pathway alterations in 90% (9/10) of cases. Unfortunately, the median duration of first-line treatment in the metastatic setting was only 3 months, highlighting the urgent need for a deeper understanding of this patient population. It was a privilege to contribute to the remarkable body of work presented by Dana-Farber Cancer Institute at this year’s SABCS. #SABCS2024 #BreastCancerResearch #DanaFarber #TranslationalResearch Sara Tolaney Giuseppe Curigliano Università degli Studi di Milano Harvard University San Antonio Breast Cancer Symposium

🩷 Pink October: Making the invisible visible This Breast Cancer Awareness Month, we focus on the unseen insights that can transform treatment outcomes. With the OncoDEEP® Kit, we’re helping oncologists make the invisible visible—uncovering critical genetic mutations that traditional tests may miss. 🧬 Discover in our Case of the Month how our analysis has revealed key mutations like PIK3CA and ESR1, which guide more personalized, effective treatments for metastatic breast cancer patients. These insights empower oncologists to adjust therapies, improving outcomes and offering renewed hope. 💪 Swipe through our carousel to see how we’re revolutionizing cancer care by making the invisible, visible. 🎗️ Discover the full case : https://lnkd.in/e8aCmiM8 Resources about breast cancer : https://lnkd.in/e95wwe7g #PinkOctober #MakingTheInvisibleVisible #BreastCancerAwareness #OncoDEEP #PrecisionMedicine #GenomicProfiling #OncoDNA

✨Highlight of Prof. Ola Khorshid MD PhD’s Talk at Breast Gynecological & Immunooncology International Cancer Conference-BGICC 17th Conference: Advancements in cancer management 🌍At BGICC 2025, Prof. Ola Khorshid discussed the shift in cancer treatment, from traditional chemotherapy to immunotherapy and targeted therapies. She emphasized the role of chronic inflammation in cancer progression and the challenges of identifying reliable biomarkers. Prof. Khorshid highlighted how immunotherapy, particularly checkpoint inhibitors (anti-PD-1/PD-L1), is now central to first-line treatments, improving survival rates. She also noted the importance of combining surgery with systemic therapies, like chemo-immunotherapy, for certain patient subsets. Despite significant progress, unmet needs remain, especially for patients with progressive disease, and ongoing trials are expanding treatment options for metastatic cancers. In conclusion, Prof. Khorshid stressed the need for personalized treatment and continuous innovation in oncology. https://lnkd.in/dhYYNFEf #Cancer #CancerResearch #BGICC #BGICC2025 #CancerConference #Medicine #Health #BreastCancer #Oncology #OncoDaily

🔬 Why Research Matters At the Prostate Cancer Centre, research isn't just a buzzword – it's our lifeline to progress. Here's why: 1️⃣ Advancing Treatment Options: Research brings forth cutting-edge therapies, surgeries, and meds for better patient outcomes. 2️⃣ Improving Early Detection: We're pioneering biomarkers & screening methods for catching prostate cancer early, paving the way for effective treatment. 3️⃣ Understanding the Disease: Delving deep into prostate cancer's causes & mechanisms guides us in tailoring treatments to each patient. 4️⃣ Enhancing Quality of Life: Our research isn't just about survival – it's about thriving. We're dedicated to improving patient well-being through supportive care interventions and addressing all aspects of living with cancer. Donate to support Prostate Cancer Research: https://lnkd.in/gjRqBPb9 Together, we're making strides in the fight against prostate cancer. Your support fuels our research and brings hope to countless lives. #WhyResearchMatters #ProstateCancerAwareness #HopeInResearch #GetChecked

New editorial: “Cancer Statistics, 2025: A Hinge Moment for Optimism to Morph into Hope?” 🔗: https://lnkd.in/eFUdecQC Accompanying the 2025 American Cancer Society Cancer Statistics report in CA: A Cancer Journal for Clinicians, Benjamin W. Corn MD and David B. Feldman PhD explore how progress in cancer control has transitioned the conversation from one of optimism to one of hope. While optimism may be passive, hope requires deliberate action. Drs. Corn and Feldman challenge oncology professionals to recognize hope as a critical component of care, particularly as cancer outcomes become increasingly controllable. OncoAlert

LUNG CANCER Cocktail with Science 5th Edition The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment. PRESIDENT OF THE CONFERENCE Giuseppe Lo Russo, MD PhD Thoracic Unit, Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT #lungcancer

Did you catch Prof. O'Byrne's presentation at the World Lung Conference this weekend? Our collaborative research, led by Dr. Arutha Kulasinghe, Prof. Kenneth O'Byrne, and Dr. Ettai Markovits, has uncovered a metabolic signature in tumor cells linked to immunotherapy resistance and overall survival in lung cancer patients. This breakthrough could pave the way for predictive biomarkers for immune checkpoint inhibitors, marking a major step forward in cancer treatment. Learn more about this pivotal work and how it’s shaping the future of cancer care. 👉https://bit.ly/3Xk3oII #lungcancer #WCLC24 #NSCLC #biomarkers #spatialbiomarker #digitalpathology #immunotherapy

“NeXT Personal demonstrated the best MRD [assay] performance we have seen in [the Royal Marsden Breast Cancer] study cohort,” said Dr. Isaac Garcia-Murillas, lead author and Staff Scientist at the Institute of Cancer Research, London. “With the ultra-sensitive performance of NeXT Personal, we see strong opportunities to impact breast cancer care and management, especially for the escalation and de-escalation of treatment.” Key data highlights from Dr. Garcia’s podium talk at ASCO 2024: - NeXT Personal’s Ultra-sensitive range enabled earlier detection of recurrence, with a median ~15-month lead time over imaging detection - 100% of patients that recurred were detected with NeXT Personal and 100% of patients that were ctDNA negative on longitudinal testing were cancer-free - NeXT Personal enabled detection of very low traces of cancer, with ~39% of all detections falling in the ultra-sensitive range below 100 PPM (below 0.01% of ctDNA) - NeXT Personal enabled substantially better sensitivity and lead times compared to other MRD assays on the same patient cohort For the full Personalis ASCO 2024 data summary, see our recent press release: https://bit.ly/3RePIN0 #PrecisionOncology #MRD #ctDNA #LiquidBiopsy